Boston, MA -- (SBWire) -- 10/10/2016 --The respiratory therapy area consists of indications that affect the respiratory system in different ways, such as the scarring of lung tissue, and excessive production of mucus in the airways, thereby decreasing lung function. Some of the key indications in this therapy area include asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging.
The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that aim to treat the disease symptoms, rather than the cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. This is most notable in CF, where patients may be prescribed a combination of drugs from several treatment categories, including mucolytic agents, bronchodilators and antibiotics. The COPD and asthma treatment landscapes employ similar symptomatic treatments, including bronchodilators and inhaled corticosteroids.
Get More Details on this Report and a Full Table of Contents at Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way
However, over the past decade the treatment of respiratory disorders has developed significantly, as has the importance for novel therapies and targeted therapies. The approval of the products Orkambi and Kalydeco, in 2014 and 2012 respectively, gave patients disease-modifying treatment options for CF. Another important entry was the first biologic drug - omalizumab - approved in 2014 for the treatment of severe asthma. The trend of developing targeted therapies continued with the approval of the maintenance treatment Nucala (mepolizumab) in November 2015.
Although the more traditional non-specific symptomatic therapies continue to have a strong presence in the respiratory disorder pipeline, the pipeline also contains promising targeted biologic therapies, which reflects their growing prominence in this therapy area. Overall, 908 products are currently in active in development for respiratory disorders.
Scope
The respiratory disorders market is characterized by entrenched, commercially successful therapies.
-Which classes of drug dominate the market?
-What additional benefits have newly approved therapies brought to the market?
-What are the future prospects for the leading brands?
The pipeline contains a range of molecule types and molecular targets, with a growing presence of targeted therapies.
-Which molecular targets appear most frequently in the pipeline?
-What are the commercial prospects for the most promising late-stage pipeline products?
Respiratory disorders clinical trials have an overall attrition rate of 89.1%.
-What are the failure rates at individual phases of clinical development?
-How do the key respiratory disorders compare in terms of clinical trial failure rate?
The respiratory disorders market is forecast to rise from a value of $28.1 billion in 2015 to $46.6 billion in 2022, at a CAGR of 7.5%.
-How much of a role will pipeline product approvals play in market growth?
-Are the large number of recently approved products expected to drive market growth?
-Will generic competition have a significant impact on the market over the forecast period?
-Which products face generic competition?
Big pharma holds a notable presence in the market.
-What are the leading companies in terms of market share?
-Which companies are forecast to experience the greatest growth in market share?
-Which company will hold the largest market share in 2022?
-How dependent are the key companies on this disease cluster for revenue?
-Which companies rely heavily on this disease cluster for revenue?
Reasons to Get This Report
This report will allow you to -
-Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment landscape in respiratory disorders.
Assess the current treatment landscape, with product profiles on prominent marketed therapies, including revenue forecasts.
-Analyze the respiratory disorders pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
-Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
-Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market
-Global Resipiratory Drugs Market 2016-2020
-Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies
-Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market
-Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth
Global Respiratory Drugs Market to 2022 - New Market Study Published
Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way